Grant: Team Grant - HIV/AIDS and comorbidities - LOI
University of Calgary
$10,000.00
Human Immunodeficiency Virus Type-1 (HIV-1) Infection and Gastrointestinal (GI) Disease
FY 2011-12
Summary
Diseases of the liver and gastrointestinal (GI) tract (digestive diseases) is an important cause of illness in patients with human immunodeficiency virus (HIV) infection. Prior to the availability of multiple HIV drugs (i.e., highly active antiretroviral therapy or HAART), patients often presented with opportunistic infections of the digestive tract with pathogens (i.e., viruses, bacteria) that would normally not cause disease in a healthy person. Although, treatment with HAART can greatly restore a patients immune system and reduce infection risk, many HIV positive patients continue to suffer from frequent gastrointestinal health problems. Over half of all patients living with HIV complain of unintentional weight loss, poor appetite, pain and diarrhea. In addition, HIV positive patients may be coinfected with hepatitis B virus or hepatitis C virus which are transmitted by similar routes of infection (i.e., by blood or body fluids). Liver disease is a leading cause of illness and premature death in HIV/hepatitis coinfected persons. We propose to assemble a multidisciplinary team of experts in infectious diseases, gastroenterology (GI) and hepatology (liver). We aim to characterize the impact of gastointestinal and liver diseases on the health and well-being of patients living with HIV before and after HAART therapy. At the Southern Alberta clinic we care for ~2800 patients living with HIV. We have collected very detailed clinical data and blood samples from our patients for ~20 years. In this study we aim to determine the extent of gastrointestinal and liver disease in our patient population, measure the economic impact on patient care (i.e, hospitalization costs, antiviral drugs), and understand the processes by which HIV, hepatitis viruses and the drugs used to treat HIV can affect GI function and cause liver disease. These studies will lead to greater understanding of how to help treat common liver and GI health problems in HIV-1 positive patients.
Department
Program
Team Grant - HIV/AIDS and comorbidities - LOI
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
247292
Name
Coffin Carla S
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
HIV/AIDS and Co-morbidities
Projecttitle
Human Immunodeficiency Virus Type-1 (HIV-1) Infection and Gastrointestinal (GI) Disease
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Team Grant - HIV/AIDS and comorbidities - LOI
Keyworddelim
Antiviral Drug Resistance; Gastrointestinal Disease; Gut Associated Lymphoid Tissue; Hbv; Hcv Lymphotropism And Viral Reservoirs; Hepatitis B Virus And Hepatitis C Virus Coinfection; Hiv; Liver Disease; Moecular Virology/ Viral Quasispecies; Viral Immunology; Woodchuck Hepatitis Virus
Abstract
Diseases of the liver and gastrointestinal (GI) tract (digestive diseases) is an important cause of illness in patients with human immunodeficiency virus (HIV) infection. Prior to the availability of multiple HIV drugs (i.e., highly active antiretroviral therapy or HAART), patients often presented with opportunistic infections of the digestive tract with pathogens (i.e., viruses, bacteria) that would normally not cause disease in a healthy person. Although, treatment with HAART can greatly restore a patients immune system and reduce infection risk, many HIV positive patients continue to suffer from frequent gastrointestinal health problems. Over half of all patients living with HIV complain of unintentional weight loss, poor appetite, pain and diarrhea. In addition, HIV positive patients may be coinfected with hepatitis B virus or hepatitis C virus which are transmitted by similar routes of infection (i.e., by blood or body fluids). Liver disease is a leading cause of illness and premature death in HIV/hepatitis coinfected persons. We propose to assemble a multidisciplinary team of experts in infectious diseases, gastroenterology (GI) and hepatology (liver). We aim to characterize the impact of gastointestinal and liver diseases on the health and well-being of patients living with HIV before and after HAART therapy. At the Southern Alberta clinic we care for ~2800 patients living with HIV. We have collected very detailed clinical data and blood samples from our patients for ~20 years. In this study we aim to determine the extent of gastrointestinal and liver disease in our patient population, measure the economic impact on patient care (i.e, hospitalization costs, antiviral drugs), and understand the processes by which HIV, hepatitis viruses and the drugs used to treat HIV can affect GI function and cause liver disease. These studies will lead to greater understanding of how to help treat common liver and GI health problems in HIV-1 positive patients.
Competitiondate
201111
Approvedterm2
1 yr 0 mth
Pinamesdelim
Coffin, Carla S; Gill, Michael J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $10,000~ $0~